INKT - MiNK Therapeutics Inc. (INKT) Q4 2023 Earnings Call Transcript
2024-03-21 14:20:05 ET
MiNK Therapeutics, Inc. (INKT)
Q4 2023 Earnings Conference Call
March 21, 2024 8:30 AM ET
Company Participants
Zack Armen - Head, Investor Relations
Jennifer Buell - President and Chief Executive Officer
Marc Van Dijk - Chief Scientific Officer
Christine Klaskin - Principal Financial and Accounting Officer
Conference Call Participants
Emily Bodnar - H.C. Wainwright
Jack Allen - Baird
Mayank Mamtani - B. Reilly Securities
Presentation
Operator
Good day everyone, and welcome to the MiNK Therapeutics' Fourth Quarter 2023 Financial Results. Today’s call is being recorded. All lines have been placed on mute to prevent any background noise and after the speakers’ remarks, there will be a question and answer session. [Operator Instructions]
I would now like to turn the conference over to Zack Armen, Head of Investor Relations. Please go ahead.
Zack Armen
Thank you, Lisa, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay.
I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans, and timelines, as well as timelines for data release and partnership opportunities among other updates. These statements are subject to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks.
Joining me today are Doctor Jennifer Buell, President and Chief Executive Officer; Christine Klaskin, Principal Financial and Accounting Officer and Doctor Marc Van Dijk, Chief Scientific Officer. Doctor Joy Zhou, Head of CMC is also here for any questions.
Now, I'd like to turn the call over to Doctor Buell to highlight our progress in 2023 and to speak to our outlook for 2024. ...
MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript